Background: Late side-effects are becoming an important issue in non-Hodgkin's lymphoma (NHL) survivors. We intended to estimate pooled relative risk (RR) of secondary malignant neoplasms (SMNs), to evaluate site-associated RR and the impact of different treatments.
introduction
Chemotherapy with or without radiation therapy has been the mainstay of non-Hodgkin's lymphoma (NHL) treatment. In the past few years, evolving therapies have led to improved long-term survival for some histological subtypes, and the introduction of monoclonal antibody treatments has further improved the prognosis of indolent [1] [2] [3] and aggressive [4] [5] [6] [7] [8] B-cell NHL. High-dose chemotherapy followed by autologous stem-cell transplantation (ASCT) and allogeneic bone marrow transplantation has emerged as another promising approach for the treatment of relapsed lymphoma or as part of planned treatment of neoplasm with a poor prognosis [9] [10] [11] [12] . As a result of these advances, the prevalence of NHL survivors is expected to increase and late side-effects of treatment such as secondary malignant neoplasms (SMNs) are becoming an important issue.
Carcinogenesis linked to specific tumor sites was highlighted as a late effect associated with exposure to chemotherapeutic drugs [13] [14] [15] [16] [17] [18] or radiotherapy [15, [19] [20] [21] as single-modality therapy, or combined-modality approaches including conventional-dose chemotherapy with radiotherapy [22] or with total body irradiation (TBI) [23] , ASTC following highdose chemotherapy [24] [25] [26] , and TBI used in the preparative regimen for ASTC [27] . Nevertheless, several studies have failed to detect a significant relationship between therapy exposure and SMNs, probably because the estimation was often based on a small number of patients. Although several previous descriptive literature reviews [28] [29] [30] [31] [32] [33] [34] [35] have discussed the risk for a second cancer, overall risk for therapy-related SMNs is less certain and the comparison of SMNs risk for NHL survivors with a general population yielded conflicting results among the studies.
Therefore, we carried out this meta-analysis to provide a quantitative assessment on the risk for SMNs. The purposes were to estimate the pooled relative risk (RR) of SMNs overall and for solid tumors, to evaluate the site-associated RR, and to examine the risk linked to treatment modality.
methods
This meta-analysis was carried out according to the guidelines proposed by the Meta-Analysis of Observational Studies in Epidemiology group [36] . We did not carry out methodological quality assessment of the studies because quality scoring in meta-analysis is controversial [37] , ad hoc scores can fail validation, and results may not be associated with quality [36, 38] . In place of a subjective quality score, we carried out subgroup and sensitivity analyses [36] .
Studies were reviewed and data extracted and cross-checked independently by two reviewers (RM and MP); disagreements were resolved by consensus with another author (LM).
search strategy
We identified studies of interest by first conducting an electronic literature search of the databases Medline and EMBASE. We used exploded Medical Subject Heading terms 'lymphoma, non-Hodgkin', 'lymphoma, t-cell', and 'lymphoma, b-cell'. The terms were combined with 'neoplasm, second primary' using the Boolean operator 'and'. In the second step, these keywords were combined using the Boolean operator 'and' with the terms 'standardized incidence ratio', 'observed to expected', and 'standardized morbidity ratio'. In addition, we reviewed the reference lists of relevant studies to identify additional relevant published articles.
selection criteria
We included studies that met each of following criteria: (i) published in English language between January 1985 and December 2008; (ii) included naive patients with any stage of NHL; (iii) investigated the risk for SMNs in NHL survivors; (iv) reported RR, specified as standardized incidence ratios or data allowing such outcomes to be derived; and (v) published as original papers (no reviews, comments, letters, or editorials).
Of the studies on specific NHL histologies, we excluded hairy cell leukemia and chronic lymphocytic leukemia because in population-based studies, these diseases are normally classified as leukemia. When two or more articles reported duplicate data, we included the most recently updated data or most informative study.
data extraction
A standardized form was used for each study included in the meta-analysis. Extracted data included paper characteristics (first author's last name, publication year, country in which the study was carried out, and data source), study design, number of NHL patients, histological subtype, mean/ median age of patients, duration of follow-up, therapy, number of cases observed with SMNs and expected number of cases, and/or RR with corresponding 95% confidence interval (CI). Where not reported, we computed the CI for the RR assuming a Poisson distribution for the observed number of cases. Standard error (SE) for the natural logarithm of RR [ln(RR)] was derived from CI, applying the following equation: SE = ln(upper 95% CI/lower 95% CI)/(2 · z 1 2 a/2 ). Cancer sites with at least three RR estimates meeting our meta-analysis criteria are reported separately. When studies showed that the observed number of cases was zero, we simply added 1 to both the observed and the expected number of cases to enable computation of an estimate of the ln(RR) and its associated SE [39] . Some authors were contacted for clarification and additional and unreported information for the metaanalysis.
statistical analysis
Statistical heterogeneity of RR across the studies was explored with the Cochran's Q test [40] and I 2 statistic [41, 42] . A P value >0.10 for the Q statistic and an I 2 value <50% was interpreted as signifying a low level of heterogeneity. The pooled estimates of RR, together with associated 95% CIs, were obtained using the DerSimonian and Laird random-effects model [43] and the Mantel-Haenszel fixed-effects model [44] , according to heterogeneity statistics. For the principal meta-analysis, we calculated pooled RR, associated with 95% CIs with fixed and random effects to evaluate the effects of any small studies [45] .
Publication bias was sought using the funnel plots and quantified using the rank correlation test as proposed by Begg and Mazumdar [46] and the regression asymmetry test by Egger et al. [47] . All statistical tests were Figure 2 . Forest plot of the meta-analysis relating risk for secondary malignancy in non-Hodgkin's lymphoma survivors. Squares represent the relative risk of each single study (size of the square reflects the study-specific statistical weight); horizontal lines represent 95% confidence intervals (CIs); diamonds represent the pooled estimates, based on the random-effects meta-analysis of the studies, with corresponding 95% CIs. F, female; M, male. Pooled relative risks (RRs) and relative 95% confidence intervals (CIs) were from fixed or random models. F, female; M, male.
original article Annals of Oncology two-sided. One-way sensitivity analysis was used to investigate the influence of each study on the overall estimate by calculating a pooled RR omitting each estimate one at a time [48] . Additionally, subgroup sensitivity analysis was carried out to evaluate the robustness of results. Meta-regressions were fitted by restricted maximum likelihood algorithm. The ln(RR) was the dependent variable, and the characteristics analyzed included type of data source (clinical trials, hospital-or specialist center-based studies, and population-based studies), average age of NHL patients (median or mean), average period of calendar recruitment of patients, and follow-up duration (<5 years, ‡5 years); for the meta-regression on all malignancies, we took into account the exposure of patients to TBI (as a dummy variable). We first conducted a univariate regression analysis for each factor, followed by a multivariate regression (including only the studies for which the factors of interest were available). A permutation test was applied to fitted models to establish the true statistical significance of a positive finding, incorporating 20 000 Monte Carlo simulations [49] . Statistical analyses were carried out using the Stata software package, version 10.1 (StataCorp, College Station, TX).
results

search results
We initially identified 1521 potentially eligible studies (Figure 1 ). After exclusion of duplicate references, nonrelevant literature, and papers that did not satisfy inclusion criteria, 47 candidate articles remained for further review. The full text of these articles was carefully read, and 24 candidate papers were excluded due to overlapping publications or nonsatisfaction of inclusion criteria [14, 15, 20, .
We used a total of 23 studies for the meta-analyses. Of these, 21 studies contributed to principal meta-analysis on the risk for SMNs and/or solid SMNs: 6 were studies from clinical trials [17, 18, [71] [72] [73] [74] , 11 were studies carried out in hospitals or specialist centers [21, 23, 27, [75] [76] [77] [78] [79] [80] [81] [82] , and 4 were populationbased studies, i.e. based on data from cancer registries [19, [83] [84] [85] . Nineteen studies were identified that provided risks for specific cancer types [17-19, 21, 23, 27, 72, 74-79, 81, 83-87] . Two studies were included in the meta-analysis, although they partially overlapped other papers. The study by Hemminki et al. [85] was included because it covered a recent time period (1999) (2000) (2001) (2002) (2003) (2004) ) not present in the previous large study by Brennan et al. [84] . The paper of Dores et al. [87] , a chapter in a multiauthored book, was included in our meta-analysis for the specific cancer sites not reported in a subsequent article [19] . The main features of the studies included in the meta-analysis and the estimated RR with 95% CIs are showed in Table 1 .
meta-analysis results
overall secondary malignancy risk. The analyzed dataset encompassed 19 articles (Table 1) . Studies included a total of 208 643 NHL survivors who developed 13 878 SMNs recruited during the period 1935-2004. Twelve studies [18, 19, 21, 23, 27, 71, 73, 78, 79, 81, 83, 84] reported positive association between risk for SMNs and previous NHL, whereas 7 [17, 74-77, 80, 82] showed no association. The statistical heterogeneity tests yielded highly significant results (Cochran's Q test, P < 0.001; I 2 = 97.5%) giving evidence of statistical heterogeneity. Figure 2 presents the results of the random-effects model meta-analysis. The pooled RR of SMNs was 1.88 (95% CI 1.58-2.22), an increased, statistically significant value in comparison with the risk of the general population. The pooled RRs calculated from each subgroup (for clinical trials, hospital-based studies, and population-based studies, RRs were 2.36, 2.11, and 1.28, respectively) were significant. The pooled RR of SMN using the fixed-effect model was 1.31 (95% CI 1.29-1.34) ( Table 2 ) and showed that any small-study effects had little impact on the intervention effect estimate.
The funnel plot was symmetric (data not shown), and the Begg-Mazumdar and Egger test results provided no evidence of publication bias.
Sensitivity analyses demonstrated the substantial stability of our results ( Figure 3A) . However, excluding the study by Barista et al. [71] that reported a very high RR, we found a lower pooled RR for all malignancies (RR = 1.63; 95% CI 1.40-1.91), and the subanalysis on studies carried out on patients from clinical trials showed no excess of risk (RR = 1.20; 95% CI 0.95-1.52).
A meta-regression analysis showed a significant positive association between ln(RR) and the follow-up ‡5 years (P = 0.038) and exposure to TBI (P = 0.002). After correction for multiple testing, only exposure to TBI was found significant (P = 0.014).
overall solid tumors risk. We did not carry out a meta-analysis for solid SMNs according to the type of studies because the (Table 1) , and 7949 patients developed solid SMNs. Two population-based studies [19, 85] and two institutional studies [21, 79] reported a significant positive association for the risk for solid SMNs and previous NHL. The statistical tests indicated substantial heterogeneity across the studies (Cochran's Q test, P < 0.001; I 2 = 97.2%). Meta-analysis carried out on all studies showed a significant association between previous NHL and the risk for solid SMNs ( Figure 4) ; the random-effects combined estimate resulted in an RR of 1.32 (95% CI 1.07-1.63). The pooled RR of SMN using the fixed-effect model was 1.25 (95% CI 1.23-1.29) ( Table 2 ) and showed that any small-study effects had little impact on the intervention effect estimate. Neither Egger's nor Begg-Mazumdar's test supported publication bias.
Sensitivity analysis ( Figure 3B ) showed that the omission in turn of each study did not appreciably change the pooled RR, and the estimates in each case were within the CI of the pooled estimate.
By regression analysis, we identified a significant association between young age at diagnosis (P = 0.011). Following a permutation test in multivariate analysis, age was revealed as having a significant influence on the ln(RR) of SMNs (P = 0.024).
site-specific incidence. [17, 18, 72, 74] , 9 were hospital-based studies [21, 23, 27, [75] [76] [77] [78] [79] 81] and 5 were population-based studies [19, [83] [84] [85] [86] . The majority of investigated sites manifested a statistically significant RR increase for solid tumors in comparison with the reference population (Table 3) . For corpus uteri, we found a significant negative association with primary NHL. Among lymphohematopoietic tumors, we did not discover significant differences with respect to the general population for second primary NHL, while an excess of risk was observed for multiple myeloma, Hodgkin's lymphoma, leukemia, and nonlymphocytic leukemia. Publication bias was not evident when the Begg and the Egger tests were used.
impact of different treatments. Table 4 presents the pooled RRs according to treatment modality. The use of any type of chemotherapy alone was associated with higher risk for SMNs. A similar result was observed in the subanalysis on patients treated only with alkylating agents, while the pooled RR of SMNs for patients who underwent treatment with cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) or CHOP-like or radiotherapy alone was raised but not statistically significant. A combined modality of treatment was significantly associated with the risk for overall SMNs but not for solid tumors.
In addition, we evaluated the effect of TBI exposure limiting the analysis to the studies that explicitly described the therapies. We examined the association between TBI exposure and overall Figure 4 . Forest plot of the meta-analysis relating risk for secondary solid tumors in non-Hodgkin's lymphoma survivors. Squares represent the relative risk of each single study (size of the square reflects the study-specific statistical weight); horizontal lines represent 95% confidence intervals (CIs); diamonds represent the pooled estimates, based on the random-effects meta-analysis of the studies, with corresponding 95% CIs. F, female; M, male; CT, data from clinical trials; HB, data from hospital-or specialist center-based studies; PB, data from population-based studies. The analysis on any type of chemotherapy presents the results derived from studies for which we were able to trace the RR only for this type of therapy; thus, we did not include the RR calculated in the studies by André et al. 2004 [17] , Bluhm et al. [21] , and Moser et al. [72] because a part of patients was treated also with radiotherapy. b The RR reported in the studies used to estimate the pooled RR for specific chemotherapeutic agents (alkylating and CHOP or CHOP-like) can include a proportion of patients undergoing radiotherapy. c The study by Lavey et al. [76] included a part of patients that did not receive Anthracycline. d The study by Guadagnolo et al. [80] was included among studies analyzed in the group of patients treated with local radiotherapy after chemotherapy because only six patients (6%) received extended-field radiotherapy or low-dose total body irradiation. RR, relative risk; CI, confidence interval; CHOP, cyclophosphamide, adriamycin, vincristine, and prednisolone. The pooled-RR in bold were statistically significant.
original article Annals of Oncology
original article Annals of Oncology risk for SMNs using the RR reported in each study, discriminating on the basis of the proportion of patients undergoing TBI ( Figure 5 ). We found a significantly increased risk for SMNs for exposed and unexposed patients; however, the risk estimated among the studies including patients undergoing TBI was higher.
discussion
This meta-analysis was designed to estimate the risk for SMNs in patients with a history of NHL. Our goals were to evaluate the RR for overall and solid SMNs, to assess site-associated RR, and to estimate the risk related to treatment modality. We showed that NHL survivors face a 1.88-fold increased risk for SMNs in comparison with the general population. When the analysis was restricted to solid tumors, we also observed an increased risk that resulted associated with younger age of patients. A statistically significant increase in risk was also found for several specific cancer types. Finally, we assessed association between treatment exposure and risk for SMNs, although we could not explore this aspect in detail because treatment information was ill described for some studies as also chemotherapy dose schedule. We found evidence of effects to exposure to chemotherapeutic agents, especially alkylating agents, alone or in combination with radiotherapy. Furthermore, a stronger association with risk for SMNs was observed for patients undergoing TBI. Our meta-analysis faces specific limitations. First, we did not search for unpublished studies, and we imposed limits on the computerized literature search, such as publication in the English language. However, the likelihood of publication bias in our results is small and not statistically significant. Secondly, we observed a very large heterogeneity among the studies. We can suggest various explanations for this variability, such as study design, NHL histology, period of recruitment, duration of follow-up, geographical and genetic variations, and therapies utilized, but we were unable to account for all these variables. Moreover, studies included in our analysis recruited patients over an extended time period , and great changes occurred in therapeutic regimes during this time. Furthermore, when we carried out the analysis for risks for specific cancer types, we found that tumors were coded according to different revisions of the International Classification of Diseases and grouped in categories that were not always homogeneous.
The strengths of our study include the use of rigorous systematic review and meta-analysis techniques to retrieve and pool data. We incorporated diverse data sources, including data from observational studies, which may obviate the risk that Figure 5 . Forest plot of relative risk of secondary malignancy in non-Hodgkin's lymphoma survivors according to exposure to total body irradiation (TBI). Squares represent the relative risk of each single study (size of the square reflects the study-specific statistical weight); horizontal lines represent 95% confidence intervals (CIs); diamonds represent the pooled estimates, based on the random-effects meta-analysis of the studies, with corresponding 95% CIs. The study by Guadagnolo et al. [80] was included among studies that provided an estimate of relative risk for patients without exposure to TBI because only six patients (6%) received extended-field radiotherapy or low-dose TBI. F, female; M, male; CT, data from clinical trials; HB, data from hospital-or specialist center-based studies; PB, data from population-based studies. clinical trial results may not be generalized to wider groups of patients [88] . Finally, our estimates of pooled RR for all and solid SMNs were substantially robust across sensitivity analyses. Several explanations may account for our demonstration of a higher overall risk of developing SMNs in NHL survivors in comparison with the general population. First, risk of therapyassociated effects in NHL survivors may contribute to increased RR. It is well known that an excess risk for bladder cancer and acute nonlymphocytic leukemia in NHL survivors is associated with alkylating agent therapy [13, 14, 16] . This chemotherapeutic agent produces DNA damage, and several DNA lesions are mutagenic, contributing to cellular transformation [89] . In our meta-analysis, we found a significant association between risk for SMNs and alkylating treatment.
The relationship between radiation therapy and SMNs is not completely clarified. Radiation therapy could trigger a multistage mechanism of carcinogenesis, significantly increasing the risk for specific types of tumors [34] . We did not find a positive significant association with SMNs, but our analysis did not consider dose, field size, treatment site, and patient age. Previous studies suggest that low-dose TBI followed by salvage chemotherapy including alkylating agents may have synergistic leukemogenic effects [23, 32] . In our analysis of all malignancies, including the data on TBI treatment resulted in a positive association with the increase of pooled RR for SMNs.
In addition to late effects of cancer therapy, other factors such as genetic instability may play simultaneous and causal roles [32, 89] . Friedman et al. [90] studied the increased risk for cancer among siblings of long-term childhood cancer survivors and discovered a statistically significant risk of 1.8 for siblings of NHL probands. In contrast, Landgren et al. [91] did not observe an excess of risk for SMNs among NHL patients with positive family histories of cancer with respect to patients lacking the family history. The contribution of shared environmental influences may be a third explanation for the high RR observed. For example, smoking is an important environmental risk factor for lung cancer, and several studies have found that patients treated for lymphoma with history of smoking had a greater risk for the development of lung cancer [92, 93] . Furthermore, Moser et al. [72] in a multivariate analysis of occurrence of SMNs have highlighted the role of tobacco use as an additional risk factor for developing SMNs, as well as of CHOP-like chemotherapy and age.
Some studies argued that the risk for SMNs after NHL appeared to be age related [18, 72, 77, 85] . We found that a younger age at NHL diagnosis was significantly associated with the risk for SMNs for solid tumors, while the RR for all malignancy increased but was not statistically significant. In contrast, a longer follow-up could allow the emergence of neoplasms with long latencies. We also consider other agerelated explanations for our observation, such as the higher susceptibility of children to the mutagenic effects of therapy and the prevalence of cell proliferation during the early stages of development [94] .
In conclusion, to the best of our knowledge, this is the first meta-analysis of SMNs in NHL survivors. Our results demonstrate that these patients experience a higher risk for SMNs than the general population and stressed the possible carcinogenic effect of chemotherapy and combined-modality therapy. To clarify the underlying mechanisms involved, it would be necessary to obtain more information on the treatments and dose schedule used. Additionally, it is important to consider the complexity of a study addressing possible interactions with genetic susceptibility and environmental exposures. 
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